Treatment of Patients With Neovascular AMD Using Indocyanine Green-Mediated Photothrombosis (i-MP).
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00331253|
Recruitment Status : Unknown
Verified April 2007 by Opto Eletronica S.A..
Recruitment status was: Recruiting
First Posted : May 29, 2006
Last Update Posted : April 27, 2007
|Condition or disease||Intervention/treatment||Phase|
|Maculopathy, Age-Related||Procedure: Indocyanine Green-Mediated Photothrombosis||Phase 2|
Comparative, controlled, multicenter, masked, randomized study, three parallel groups, comparing the Indocyanine Green-Mediated Photothrombosis to two control groups, for the treatment of neovascular Age-Related Macular Degeneration.
Only patients matching the following criteria are eligible:
A. BCVA worse than 20/80 and neovascular complex with some component of occult CNV as defined by the fluorescein angiography, or; B. BCVA worse than 20/80 and neovascular complex with total area of CNV (classic and occult) by fluorescein angiography occupying an area lesser than 50% of the neovascular complex, or; C. BCVA worse than 20/200 and neovascular complex with some CNV (classic OR occult) by fluorescein angiography.
The eligibility of the patients will be assessed by an independent Centre of Interpretation after masked analysis.
Eligible patients will be allocated into one of the three study groups, randomized at 2:1:1 proportion:
Group 1: Treatment Procedure #1 = i-MP (ICG + Laser), at proportion of 2. In this group the patients will be submitted to endovenous infusion of ICG followed by irradiation with diode laser.
Group 2: Treatment Procedure #2 (Distilled water + Laser), at proportion of 1. In this group the patients will receive endovenous placebo infusion (distilled water) followed by irradiation with diode laser with same power utilized in Group 1.
Group 3: Treatment Procedure #3 (Distilled water + Sham Laser), at proportion of 1. In this group the patients will receive endovenous placebo infusion (distilled water) followed by simulated application of laser.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||280 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A 54-WEEK, PHASE 2, MULTICENTER, MASKED, RANDOMIZED, CONTROLLED TRIAL TO ESTABLISH THE SAFETY AND EFFICACY OF INDOCYANINE GREEN-MEDIATED PHOTOTHROMBOSIS (i-MP) FOR THE TREATMENT OF PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.|
|Study Start Date :||April 2007|
|Estimated Study Completion Date :||December 2008|
- Compare the groups in respect to proportion of eyes that lost less than 15 letters in ETDRS BCVA from baseline at week-54
- Compare the groups in respect to proportion of eyes that did not present any loss in ETDRS BCVA (2 letters change) from baseline at week-54
- Compare the groups in respect to mean change in ETDRS BCVA
- Compare the groups in respect to neovascular complex activity (size and CNV leaking area)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00331253
|Contact: Elizeu Ramos, M.S.||55 16 33737023||ELIZEU@opto.com.br|
|Contact: Rogério Costa, M.D.||55 16 firstname.lastname@example.org|
|Study Director:||Elizeu Ramos, M.S.||Opto Eletrônica S.A.|
|Principal Investigator:||Avila Marcos, MD||Universidade Federal de Goias|